Early treatment trial of hydroxychloroquine shows no symptomatic benefit for COVID-19 patients
Adult outpatients with mild symptoms of COVID-19 don’t benefit from taking hydroxychloroquine
A good showing for the IDIGH Program in 2020-2021 FRQS awards
Congratulations to researchers and trainees!
Recipient of the 2020-2021 Dr. Margaret Becklake Fellowship: Mikashmi Kohli
A postdoctoral fellow from the RI-MUHC is recognized for international work on TB diagnostics
Three COVID-19 projects at the RI-MUHC to receive CIHR funding
A $109M fund aims to mitigate impact of the pandemic on care delivery in Canada and beyond, as well as contribute to better understanding of the disease
COVID-19 pandemic: Looking back to better tackle future challenges
In two recent studies, RI-MUHC researchers provide useful information for evaluating public health strategies
Innovation Moves Online for the 2020 McGill Clinical Innovation Competition
RI-MUHC research team, Emily McDonald and Todd C. Lee, ties for Marika Zelenka Roy Innovation Prize
COVID-19 impact on cancer patients: MUHC researchers take part in a multinational study
Published in The Lancet, the study reveals cancer-specific factors associated with increased mortality
Hydroxychloroquine not effective in preventing the development of COVID-19 when used as post-exposure prophylaxis
A new study suggests that hydroxychloroquine is not effective in preventing the development of COVID-19 in individuals exposed to SARS-CoV-2
Results of MI4 Emergency COVID-19 Research Funding (Round 2)
RI-MUHC researchers awarded MUHC Foundation funding for a second round of projects with potential impact in a short timeframe
Looking to produce a COVID-19 vaccine in the greenhouse
RI-MUHC researcher working with Quebec-based company on a plant-based technique